Quick Answer
Prelude Therapeutics Inc reported Net Income Loss of -$99.50 million for the year ending 2025.
- Prelude Therapeutics Inc showed an increase of +21.8% in Net Income Loss from 2024 to 2025.
- This data is from Prelude Therapeutics Inc's annual report (Form 10-K), filed with the SEC on March 10, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 7 years of available data (2019 to 2025), Prelude Therapeutics Inc's Net Income Loss has declined by 260.9%.
- Historical annual values: Fiscal year 2025: -$99.50 million | Fiscal year 2024: -$127.17 million | Fiscal year 2023: -$121.83 million | Fiscal year 2022: -$115.44 million | Fiscal year 2021: -$111.69 million | Fiscal year 2020: -$56.93 million | Fiscal year 2019: -$27.57 million.
- Data sourced from SEC EDGAR public filings as of June 21, 2026.
Last verified: